LOUHI

Our next-generation technology targets chronic respiratory diseases by dismantling the bacterial biofilm—the protective shield that makes these infections so difficult to cure. By breaking this barrier, our approach restores the clinical power of standard antibiotics. For patients and healthcare systems, this means shorter treatment cycles, drastically reduced antibiotic exposure, and a significantly lighter burden and cost on society.

The LOUHI project presents a highly unique commercial opportunity driven by an expanding global market, compelling value-based economics, and a streamlined regulatory pathway for rare diseases.